The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

Survival and new cancers with myeloproliferative neoplasms.

Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.

Quality of life and disease understanding: impact of attending a patient-centered cancer symposium.

The need for United States-based guidelines for myeloproliferative neoplasms.

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

Profile of pomalidomide and its potential in the treatment of myelofibrosis.